1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

ADA 2020: US Pivotal Trial Data Support Medtronic’s Next-Gen Insulin Pump

 
• By Reed Miller

Clinical data presented during the virtual ADA meeting show Medtronic’s MinMed 780G hybrid closed-loop insulin system, an upgraded version of the company's 770G system, improved patients’ ability to keep their blood-glucose levels within target range.

Molecular model of insulin molecule, 3D illustration
3D model of an insulin molecule

New 90-day results from the US pivotal trial of Medtronic PLC's MiniMed 780G insulin pump show the next-generation system safely improves users’ “time in range” (70-180 mg/dL) – the percentage of time the users’ blood glucose is near the optimal level – without increasing hypoglycemia.

Primary investigator Anders Carlson of the Park Nicollet International Diabetes Center in Minneapolis presented results from the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Medtronic Presents Data To Boost Hugo’s Odds Of Getting FDA Nod

 
• By Brian Bossetta

Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.

First Liver Cancer Surveillance Test In Five Years Receives FDA Breakthrough Status

 
• By Natasha Barrow

Cambridge-based startup Mursla Bio's liquid biopsy test EvoLiver uses extracellular vesicles to detect hepatocellular carcinoma (HCC) in high-risk cirrhotic patients. Medtech Insight sat down with with Mursla Bio CEO Pierre Arsène.

Biolinq’s $100M In Series C Financing Supports Efforts To Bring Diabetic Glucose Monitoring With Needle-Free Patch To Market

 
• By Marion Webb

Biolinq plans to use the proceeds of its new venture funding to support US FDA de novo review, automation engineering and commercialization efforts with partners, CEO Rich Yang told Medtech Insight.